Epiendo
Develops drugs that target epithelial differentiation, regeneration, and barrier function.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €20.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Developer of drugs and proprietary compounds intended to offer new treatments for chronic airway diseases. The company specializes in developing novel and proprietary drugs that preserve the barrier-enhancing effects of azithromycin and uses a non-antibiotic macrolide platform that addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases, enabling healthcare professionals to provide patients with the right treatment to improve their lives.
Keywords: Pharmaceuticals and Biotechnology, Barrier Enhancement, Cellular Barrier, Chronic Respiratory Disease, Effects Of Azithromycin, Epithelial Barrier, Epithelial Integrity, Epithelial Tissue, Non-Antibiotic Macrolide.